Dermira, Inc. (DERM) News
Filter DERM News Items
DERM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
DERM News Highlights
- For DERM, its 30 day story count is now at 20.
- Over the past 21 days, the trend for DERM's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about DERM are DRUG, LYRA and AGE.
Latest DERM News From Around the Web
Below are the latest news stories about JOURNEY MEDICAL CORP that investors may wish to consider to help them evaluate DERM as an investment opportunity.
Here's What Could Help Journey Medical Corporation (DERM) Maintain Its Recent Price StrengthJourney Medical Corporation (DERM) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. |
The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive TherapeuticsAmphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics are part of the Zacks top Analyst Blog. |
What Awaits These 4 Drug Stocks That More Than Doubled in 2023?Here are four drug, biotech stocks, AMPH, DERM, CNTA & AQST, which have more than doubled in 2023 with room for further growth in 2024. |
argenx (ARGX) Tanks on Top-Line Data From Pemphigus Studyargenx's (ARGX) phase III ADDRESS study, evaluating efgartigimod subcutaneous for treating pemphigus, fails to meet primary and secondary endpoints. Stock falls. |
Anavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAAThe CHMP agrees that Anavex's (AVXL) blarcamesine for Alzheimer's disease is eligible for submission for a Union Marketing Authorisation in the EU. Shares rise. |
4 Drug Stocks Rising More Than 40% in 2023 With Room to GrowNovo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024. |
Invivyd (IVVD) Surges on Positive Data From COVID-19 StudyInvivyd (IVVD) reports positive initial data from the phase III CANOPY study on VYD222 for the prevention of symptomatic COVID-19. Stock shoots up on the news. |
Arcutis (ARQT) Up on FDA Nod for Zoryve in Seborrheic DermatitisThe FDA approves Arcutis' (ARQT) NDA for Zoryve topical foam 0.3% for treating seborrheic dermatitis in individuals nine years of age and above. |
Journey Medical Corporation (NASDAQ:DERM) Surges 69% Yet Its Low P/S Is No Reason For ExcitementDespite an already strong run, Journey Medical Corporation ( NASDAQ:DERM ) shares have been powering on, with a gain of... |
Apellis (APLS) Falls on Europe Update for Pegcetacoplan in GAThe CHMP may adopt a negative opinion on Apellis' (APLS) intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration in the EU. Stock declines. |